Advertisement
| brca therapy for prostate cancer: Molecular Biology of Prostate Cancer Manfred Wirth, J. E. Altwein, B. Schmitz-Dräger, S. Kuptz, 2013-05-22 |
| brca therapy for prostate cancer: Cancer and the Environment Institute of Medicine, Board on Health Sciences Policy, Roundtable on Environment Health Sciences, Research, and Medicine, 2002-08-01 The Roundtable on Environmental Health Sciences, Research, and Medicine wanted to address the link between environmental factors and the development of cancer in light of recent advances in genomics. They asked what research tools are needed, how new scientific information can be applied in a timely manner to reduce the burden of cancer, and how this can be flexible enough to treat the individual. |
| brca therapy for prostate cancer: Prostate Cancer Scott M. Dehm, Donald J. Tindall, 2020-01-03 The purpose of this book is to provide a contemporary overview of the causes and consequences of prostate cancer from a cellular and genetic perspective. Written by experts in the fields of epidemiology, toxicology, cell biology, genetics, genomics, cell-cell interactions, cell signaling, hormone signaling, and transcriptional regulation, the text covers aspects of prostate cancer from disease initiation to metastasis. Chapters explore in depth the cells of origin for prostate cancer, its genomic subtypes, neural transcription factors in disease progression, epigenetic regulation of chromatin, and many other topics. This book distinguishes itself from other texts on prostate cancer by its focus on cellular and genetic mechanisms, as opposed to clinical diagnosis and management. As a result, this book will be of broad interest to basic and translational scientists with familiarity of these topics, as well as to trainees at earlier stages of their research careers. |
| brca therapy for prostate cancer: Genome Stability Igor Kovalchuk, Olga Kovalchuk, 2021-07-17 Genome Stability: From Virus to Human Application, Second Edition, a volume in the Translational Epigenetics series, explores how various species maintain genome stability and genome diversification in response to environmental factors. Here, across thirty-eight chapters, leading researchers provide a deep analysis of genome stability in DNA/RNA viruses, prokaryotes, single cell eukaryotes, lower multicellular eukaryotes, and mammals, examining how epigenetic factors contribute to genome stability and how these species pass memories of encounters to progeny. Topics also include major DNA repair mechanisms, the role of chromatin in genome stability, human diseases associated with genome instability, and genome stability in response to aging. This second edition has been fully revised to address evolving research trends, including CRISPRs/Cas9 genome editing; conventional versus transgenic genome instability; breeding and genetic diseases associated with abnormal DNA repair; RNA and extrachromosomal DNA; cloning, stem cells, and embryo development; programmed genome instability; and conserved and divergent features of repair. This volume is an essential resource for geneticists, epigeneticists, and molecular biologists who are looking to gain a deeper understanding of this rapidly expanding field, and can also be of great use to advanced students who are looking to gain additional expertise in genome stability. - A deep analysis of genome stability research from various kingdoms, including epigenetics and transgenerational effects - Provides comprehensive coverage of mechanisms utilized by different organisms to maintain genomic stability - Contains applications of genome instability research and outcomes for human disease - Features all-new chapters on evolving areas of genome stability research, including CRISPRs/Cas9 genome editing, RNA and extrachromosomal DNA, programmed genome instability, and conserved and divergent features of repair |
| brca therapy for prostate cancer: Assessing Genetic Risks Institute of Medicine, Committee on Assessing Genetic Risks, 1994-01-01 Raising hopes for disease treatment and prevention, but also the specter of discrimination and designer genes, genetic testing is potentially one of the most socially explosive developments of our time. This book presents a current assessment of this rapidly evolving field, offering principles for actions and research and recommendations on key issues in genetic testing and screening. Advantages of early genetic knowledge are balanced with issues associated with such knowledge: availability of treatment, privacy and discrimination, personal decision-making, public health objectives, cost, and more. Among the important issues covered: Quality control in genetic testing. Appropriate roles for public agencies, private health practitioners, and laboratories. Value-neutral education and counseling for persons considering testing. Use of test results in insurance, employment, and other settings. |
| brca therapy for prostate cancer: Successes and Limitations of Targeted Cancer Therapy S. Peters, R.A. Stahel, 2014-02-19 The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor. Targeting specific molecular pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy, recognizing and dealing with side effects and, importantly, the development of resistance. This book provides an up-to-date overview of the advances and limitations of targeted therapy for several tumor entities including breast cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, melanoma, ovarian cancer and renal cell carcinoma. Written by over a dozen internationally renowned scientists, the book is suitable for advanced students, postdoctoral researchers, scientists and clinicians who wish to update their knowledge of the latest approaches to targeted cancer therapies. |
| brca therapy for prostate cancer: DNA Damage, DNA Repair and Disease Miral Dizdaroglu, R Stephen Lloyd, 2020-11-11 The DNA of all organisms is constantly being damaged by endogenous and exogenous sources. Oxygen metabolism generates reactive species that can damage DNA, proteins and other organic compounds in living cells. Exogenous sources include ionizing and ultraviolet radiations, carcinogenic compounds and environmental toxins among others. The discovery of multiple DNA lesions and DNA repair mechanisms showed the involvement of DNA damage and DNA repair in the pathogenesis of many human diseases, most notably cancer. These books provide a comprehensive overview of the interdisciplinary area of DNA damage and DNA repair, and their relevance to disease pathology. Edited by recognised leaders in the field, this two-volume set is an appealing resource to a variety of readers including chemists, chemical biologists, geneticists, cancer researchers and drug discovery scientists. |
| brca therapy for prostate cancer: The Genetics of Cancer B.A. Ponder, M.J. Waring, 2012-12-06 It has been recognized for almost 200 years that certain families seem to inherit cancer. It is only in the past decade, however, that molecular genetics and epidemiology have combined to define the role of inheritance in cancer more clearly, and to identify some of the genes involved. The causative genes can be tracked through cancer-prone families via genetic linkage and positional cloning. Several of the genes discovered have subsequently been proved to play critical roles in normal growth and development. There are also implications for the families themselves in terms of genetic testing with its attendant dilemmas, if it is not clear that useful action will result. The chapters in The Genetics of Cancer illustrate what has already been achieved and take a critical look at the future directions of this research and its potential clinical applications. |
| brca therapy for prostate cancer: Clinical Guide to Antineoplastic Therapy Mary Magee Gullatte, 2014 Get the latest information on antineoplastic use and patient care when you purchase your copy of the essential chemotherapy resource for cancer-care professionals. Newly updated, revised, and expanded, the third edition of the Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook serves as an up-to-date reference for clinicians at every level from students and novices to the most seasoned nurses and other healthcare professionals involved in the care of patients receiving chemotherapy. Edited by Mary Magee Gullatte, this comprehensive guide features chapters on the fundamentals of antineoplastic therapy, commonly used regimens for specific cancers, clinical trials, reimbursement for chemotherapy, botanicals and other complementary and alternative therapies, vascular access devices, and symptom management, as well as an easy-to-use A Z guide of more than 150 chemotherapy, biotherapy, and hormonal therapy agents. New to this edition are chapters on patient navigati |
| brca therapy for prostate cancer: Targeting Cell Survival Pathways to Enhance Response to Chemotherapy , 2018-03-28 Targeting Cell Survival Pathways to Enhance Response to Chemotherapy encompasses recently developed molecular targeting agents and approaches that suppress cell survival signaling. Cell survival signaling attenuates the effectiveness of conventional chemotherapy and numerous mechanisms have been described, and continue to be described, which contribute to cell survival in the face of chemotherapy treatment. Key pathways leading to chemoresistance emanate from growth factor receptors, PI3K, STAT3, anti-apoptotic Bcl-2 family members, autophagy, and the DNA damage response pathway. New advances have underscored the potential of targeting each of these cell survival mechanisms to improve responsiveness to chemotherapy. This book reviews these recent advances and provides a foundational background and hints of new opportunities for basic, translational, and clinical investigators focused on improving therapeutic responses to chemotherapy. - Presents cutting-edge agents and approaches with proved success in different model systems that can be translated to a different type of cancer - Brings updated information to be used to propose new clinical trials investigating innovative strategies for improving responses to chemotherapy - Provides mechanistic details to help guide the design of laboratory studies associated with clinical trials |
| brca therapy for prostate cancer: Stereotactic Body Radiation Therapy Simon S. Lo, Bin S. Teh, Jiade J. Lu, Tracey E. Schefter, 2012-08-28 Stereotactic body radiation therapy (SBRT) has emerged as an important innovative treatment for various primary and metastatic cancers. This book provides a comprehensive and up-to-date account of the physical/technological, biological, and clinical aspects of SBRT. It will serve as a detailed resource for this rapidly developing treatment modality. The organ sites covered include lung, liver, spine, pancreas, prostate, adrenal, head and neck, and female reproductive tract. Retrospective studies and prospective clinical trials on SBRT for various organ sites from around the world are examined, and toxicities and normal tissue constraints are discussed. This book features unique insights from world-renowned experts in SBRT from North America, Asia, and Europe. It will be necessary reading for radiation oncologists, radiation oncology residents and fellows, medical physicists, medical physics residents, medical oncologists, surgical oncologists, and cancer scientists. |
| brca therapy for prostate cancer: The Comprehensive Cancer Center Mahmoud Aljurf, Navneet S. Majhail, Mickey B.C. Koh, Mohamed A. Kharfan-Dabaja, Nelson J. Chao, 2021-10-28 This open access book provides a valuable resource for hospitals, institutions, and health authorities worldwide in their plans to set up and develop comprehensive cancer care centers. The development and implementation of a comprehensive cancer program allows for a systematic approach to evidence-based strategies of prevention, early detection, diagnosis, treatment, and palliation. Comprehensive cancer programs also provide a nexus for the running of clinical trials and implementation of novel cancer therapies with the overall aim of optimizing comprehensive and holistic care of cancer patients and providing them with the best opportunity to improve quality of life and overall survival. This book's self-contained chapter format aims to reinforce the critical importance of comprehensive cancer care centers while providing a practical guide for the essential components needed to achieve them, such as operational considerations, guidelines for best clinical inpatient and outpatient care, and research and quality management structures. Intended to be wide-ranging and applicable at a global level for both high and low income countries, this book is also instructive for regions with limited resources. The Comprehensive Cancer Center: Development, Integration, and Implementation is an essential resource for oncology physicians including hematologists, medical oncologists, radiation oncologists, surgical oncologists, and oncology nurses as well as hospitals, health departments, university authorities, governments and legislators. |
| brca therapy for prostate cancer: HER2-Positive Breast Cancer Sara Hurvitz, Kelly McCann, 2018-07-26 Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists. - Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive. - Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations. - Includes a timely section on innovative future therapies. |
| brca therapy for prostate cancer: The Longevity Diet Valter Longo, 2018-02-08 Live healthier for longer with the international bestselling guide that will change your life 'The diet that holds the key to staying young . . . Dr Valter Longo is now considered one of the most influential voices in the 'fasting movement' The Times 'Dr Valter Longo is one of the real scientific pioneers when it comes to researching the impact of food on health' Dr Michael Mosley, bestselling author of The Fast Diet and The Clever Guts Diet ________ This is the clinically tested, revolutionary and straightforward diet to help you slow-down ageing, fight disease and lose weight. Following 30 years of research, Professor Valter Longo - a biochemist and one of the world's leading researchers into ageing - discovered that the secret of longevity lies in cellular regeneration triggered by a special diet. And that by adhering to his fasting-mimicking diet, we can heal ourselves through food. The Longevity Diet will guide you through the process with: - An easy-to-adopt lifetime plan - Fasting-mimicking diet 3-4 times a year, just 5 days at a time - 30 easy and delicious recipes based on Longo's 'Five Pillars of Longevity' In this lifelong, health-boosting plan, you will feel the benefits of fasting without the hunger and live a longer, healthier and more fulfilled life. And you'll get to try easy, plant-and-fish based recipes . . . - Great for the heart and rich in antioxidants: black rice with courgette and shrimp - For a good source of iron, snack on dark chocolate and yoghurt - For dessert try tangy dried cranberries and walnuts ________ Make simple changes that can extend your healthy lifespan * Prevent age-related muscle and bone loss * Build your resistance to diabetes, cardiovascular disease, Alzheimer's and cancer * Maintain your ideal weight and reduce abdominal fat |
| brca therapy for prostate cancer: Translational Advances in Gynecologic Cancers Michael Birrer, Lorenzo Ceppi, 2017-01-25 Translational Advances in Gynecologic Cancers straddles the bench and bed divide by highlighting important and interesting research that is translatable to the clinic. The contents of this book cover the entire spectrum, from promising laboratory based research, to clinical trial efforts. Further, new therapeutic indications based upon randomized phase III trials are also included. Clinicians will learn about lab-based science that is about to enter the clinic, along with the rationale behind translational endpoints in trials. Researchers will be able to identify and understand the clinical needs of patients with these types of tumors to improve their research focus. - Provides a comprehensive description of all evolving translational gynecologic cancer research for clinicians - Identifies knowledge gaps to inform the next research direction - Ties together clinical research and patient needs to help both the researcher and clinician - Addresses genomics, new target therapies, novel tools, and more for ovarian, endometrial, and cervical cancer |
| brca therapy for prostate cancer: Antineoplastons Burzynski Research Institute, 1988 |
| brca therapy for prostate cancer: Clinical Cancer Genetics Kenneth Offit, 2030-05-07 Written by a world-recognized leader in this emerging field, Clinical Cancer Genetics provides an updated and expanded treatment of Kenneth Offit's seminal text on the clinical management associated with syndromes of cancer predisposition, with a thorough review of the relevant molecular genetics. This second edition features new coverage of pharmacogenetics, gene therapy trials, high throughput genotyping, and microarrays and includes a new focus on epigenetic events in carcinogenesis within background chapter on cancer genetics. Expanded coverage highlights more uncommon and rare cancer predisposition syndromes. |
| brca therapy for prostate cancer: The MD Anderson Manual of Medical Oncology Hagop M. Kantarjian, Robert A. Wolff, Charles A. Koller, 2006-03-22 A concise, up-to-date clinician's guide to cancer management -- from the leaders in the field A Doody's Core Title! The MD Anderson Cancer Center is ranked as the world's leading institution in cancer medicine. With publication of the MD Anderson Manual of Medical Oncology, the editorial board of this prestigious institution makes available for the first time a resource that meets the needs of clinicians for an authoritative, accessible guide to the medical management of patients with cancer and its complications. Straight-to-the-point, state-of-the-art strategies for cancer management Gives physicians a current, coherent approach to each disease and situation -- imbued with the clinical expertise and teaching authority of world class oncology researchers/practitioners Consistently formatted for a unified patient management strategy Packed with time-saving features, including “The M.D. Anderson Work-Up Box” and “The M.D. Anderson Preferred Treatment Box” Examines special issues in breast cancer management…current treatment strategies for infection in the neutropenic patient and management of fungal and viral infections in cancer patients… basic concepts and controversies related to allogeneic marrow transplantation…more Provides guidelines for oncologic emergencies and palliative care Outlines procedures for symptom control in long-term survival… long-term follow-up in pediatric and adult patients…and rehabilitation |
| brca therapy for prostate cancer: Avoiding Cancer One Day at a Time Lynne Eldridge, Lynne Stoesz-Eldridge, David Borgeson, 2006-12 The mortality rate from cancer hasn't changed in 60 years despite the billions invested to find a cure. Avoiding Cancer One Day At A Time provides solid, practical advice for preventing cancer by avoiding carcinogens and implementing lifestyle/dietary practices that modify cancer causing factors. Combining their experience in family medicine and epidemiology with their passion for disease prevention, the authors provide the most up to date and effective advice for preventing cancer from developing in ourselves and our loved ones. Many ?how to? examples for preventing cancer by being environmentally aware, avoiding infections, living the proper lifestyle and getting the proper nutrition are provided. Chapter by chapter summaries and listings of the latest cancer prevention web sites are great references. Worksheets assist readers in implementing the advice in very tangible ways, and the recipe collection of cancer avoiding meals is a winner! |
| brca therapy for prostate cancer: Cancer Genetics: A Clinical Approach Xavier Llor, Erin Wysong Hofstatter, 2021-11-19 The ultimate guide to caring for and communicating with patients suffering with hereditary cancer syndromes Providing the essential tools needed to understand clinical cancer genetics, Cancer Genetics: A Clinical Approach builds your mastery of differential diagnosis formulation, all the available genetic testing options at your disposal, interpreting results logically and accurately, and educating patients and their families about effective cancer prevention methods. This unparalleled resource walks you through the process of effectively and thoughtfully counseling patients—from pre-test counseling and relaying test results to navigating the legal implications of hereditary conditions and coping with the resulting psychological challenges. Cancer Genetics: A Clinical Approach is ideal for both specialized cancer genetics clinics or any healthcare professional seeking to improve their skills in identifying patients with possible hereditary cancer syndromes and recognizing which ones should be referred to a high-risk/clinical genetics specialty program. |
| brca therapy for prostate cancer: Molecular Profiling Virginia Espina, Lance Liotta, 2011-11-12 The next revolution in molecular medicine is the application of molecular profiling to individualized patient therapy. Molecular profiling technology has advanced dramatically, particularly in the field of cancer tissue biomarkers. It is now possible to gather complex genomic and proteomic information from a routine clinical needle biopsy or surgical specimen. In Molecular Profiling : Methods and Protocols, expert researchers in the field focus on the entire process from discovery to commercialization, with practical guides that are not limited to experimental methods. Written in the highly successful Methods in Molecular BiologyTM series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, as well as essays and guidelines for grants, patents, and commercialization of products related to molecular profiling. Authoritative and practical, Molecular Profiling: Methods and Protocols seeks to aid scientists in understanding the latest advancements in genomics, proteomics, imagining, and bioinformatics. |
| brca therapy for prostate cancer: Twisting Fate Pamela Munster, 2018-09-25 From a woman who’s made her living researching breast cancer—and who lived through it herself—a personal yet practical guide to the medical and emotional facets of this life-changing diagnosis A leading oncologist at the University of California San Francisco, Dr. Pamela Munster has advised thousands of women on how to cope with the realities of breast cancer, from diagnosis through treatment and recovery. But her world turned upside down when, at forty-eight years old and in otherwise perfect health, she got a call saying that her own mammogram showed “irregularities.” That single word thrust her into a wholly new role—as patient, and not only that of cancer but of the feared BRCA gene mutation as well. Suddenly, she realized that being a true “expert” in a disease was far beyond the scope of her medical training, and that she had a lot to learn if she wanted to hold onto her precious life. Weaving together her personal story with groundbreaking research on BRCA—responsible for breast cancer and many other inherited cancers affecting both women and men—Twisting Fate is an inspiring guide to living with the uncertainties of cancer. With authority, insight, and compassion, Dr. Munster uses her voice to create a safe space for genuine healing and honesty in a world otherwise too-often dominated by fear—and she is living proof of how important it is to embrace all the twists and turns of fate. |
| brca therapy for prostate cancer: Cancer Susceptibility Michelle Webb, 2010-09-02 Over the past two decades, spectacular advances have been made in our understanding of the molecular genetics of cancer, leading to the pursuit of identifying genes that, when mutated, result in an increased susceptibility to the disease. In Cancer Susceptibility: Methods and Protocols, experts in the field bring together the most recent technological developments for identifying and screening cancer susceptibility genes. Divided into two clear sections, the book begins with gene identification, which updates and informs scientists working at identifying novel cancer susceptibility genes, while the second part deals with mutation screening technologies that aid scientists and clinicians working to translate this knowledge into the clinic. Written in the highly successful Methods in Molecular BiologyTM series format, chapters contain introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and notes on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Cancer Susceptibility: Methods and Protocols is a timely collection that seeks to provide researchers with the tools to predict and combat this terrible disease. |
| brca therapy for prostate cancer: Upper Urinary Tract Urothelial Carcinoma Michael Grasso III, Demetrius H. Bagley, 2016-10-15 Upper Urinary Tract Urothelial Carcinoma was at one time felt to be a somewhat rare entity. With the success of various treatments for bladder urothelial carcinoma, the incidence of this disease in the uretere and kidney is rising. Many medical subspecialists encounter these complex patients and a multimodality treatment plan is often required for care. |
| brca therapy for prostate cancer: UK Guidance on Radiation Protection Issues Following Permanent Iodine-125 Seed Prostate Brachytherapy , 2012 |
| brca therapy for prostate cancer: Concise Handbook of Familial Cancer Susceptibility Syndromes , 2008 |
| brca therapy for prostate cancer: Achieve for Introduction to Genetic Analysis 1-term Access Anthony J. F. Griffiths, John Doebley, David A. Wassarman, Catherine Peichel, 2020-11-13 |
| brca therapy for prostate cancer: DeVita, Hellman, and Rosenberg's Cancer Vincent T DeVita Jr, Steven A Rosenberg, Theodore S Lawrence, 2022-09-21 The standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and presentation. Drs. Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg oversee an outstanding team of expert contributing authors who keep you up to date and fully informed in this fast-changing field. This award-winning reference is also continually updated on Health Library and VitalSource platforms for the life of the edition. |
| brca therapy for prostate cancer: Therapy Resistance in Prostate Cancer Hisham Bahmad, 2023-10-24 Prostate cancer (PCa) is among the most diagnosed cancers in men worldwide as well as one of the most common causes of cancer-related deaths. Despite the advances in treatment, the disease remains associated with poor survival and resistance to cytotoxic and targeted therapies. Therapy Resistance in Prostate Cancer: Mechanisms and Insights highlights the main mechanisms that are responsible for therapy resistance in PCa allowing researchers and clinicians to have a synopsis of current options and new therapies that can be proposed to overcome this resistance. Understanding the mechanisms responsible for chemotherapy resistance helps researchers all over the world to delve deeper into the pathways behind this resistance and potentially discover new therapeutic targets for PCa. - Tackles the topic of resistance from a broader perspective, including, but not limited to, the role of the extracellular matrix and cancer stem cells in therapy resistance - Creates understanding on how to develop novel therapies that specifically target CSCs to eliminate the regenerating capacity of the tumor and overcome therapy resistance - Helps in identifying novel molecular biomarkers and potential therapeutic targets pertaining to the tumor microenvironment to overcome therapy resistance - Provides a general view of the main pathways involved in PCa progression that will aid in understanding the mechanisms responsible for chemotherapy resistance |
| brca therapy for prostate cancer: Managing BRCA Mutation Carriers Anees B. Chagpar, 2017-07-13 As there are a number of nuances in terms of how to manage mutation carriers (both with and without a concomitant diagnosis of breast cancer), this text provides a comprehensive, state-of-the art review of this field. It represents a valuable resource for a myriad of clinicians and healthcare personnel who interface with these patients. The text discusses the latest recommendations for genetic counseling and risk assessment, provides a framework for considering reducing risk in mutation carriers who do not present with a concomitant diagnosis of breast cancer, and finally elucidates the many considerations of managing a breast cancer patient with a BRCA mutation. The text presents a multidisciplinary approach gleaning insights from imaging, breast surgery, gynecology, plastic surgery, medical oncology, radiation oncology and psycho-oncology. Managing BRCA Mutation Carriers will be a useful resource for physicians and healthcare providers from a myriad of disciplines who manage BRCA mutation carriers. All chapters are written by experts in their fields and include the most up to date scientific and clinical information. |
| brca therapy for prostate cancer: Prostate Cancer: New Insights for the Healthcare Professional: 2012 Edition , 2012-12-10 Prostate Cancer: New Insights for the Healthcare Professional / 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Prostate Cancer. The editors have built Prostate Cancer: New Insights for the Healthcare Professional / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Prostate Cancer in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Prostate Cancer: New Insights for the Healthcare Professional / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/. |
| brca therapy for prostate cancer: Twisting Fate: My Journey with BRCA - from Breast Cancer Doctor to Patient and Back Pamela Munster, 2018-09-25 From a woman who’s made her living researching breast cancer—and who lived through it herself—a personal yet practical guide to the medical and emotional facets of this life-changing diagnosis A leading oncologist at the University of California San Francisco, Dr. Pamela Munster has advised thousands of women on how to cope with the realities of breast cancer, from diagnosis through treatment and recovery. But her world turned upside down when, at forty-eight years old and in otherwise perfect health, she got a call saying that her own mammogram showed “irregularities.” That single word thrust her into a wholly new role—as patient, and not only that of cancer but of the feared BRCA gene mutation as well. Suddenly, she realized that being a true “expert” in a disease was far beyond the scope of her medical training, and that she had a lot to learn if she wanted to hold onto her precious life. Weaving together her personal story with groundbreaking research on BRCA—responsible for breast cancer and many other inherited cancers affecting both women and men—Twisting Fate is an inspiring guide to living with the uncertainties of cancer. With authority, insight, and compassion, Dr. Munster uses her voice to create a safe space for genuine healing and honesty in a world otherwise too-often dominated by fear—and she is living proof of how important it is to embrace all the twists and turns of fate. |
| brca therapy for prostate cancer: Complementary and Alternative Medicines in Prostate Cancer K. B. Harikumar, 2016-12-01 Recent global cancer statistical data has clearly indicated that prostate cancer is currently the second most frequently diagnosed cancer (at 15% of all male cancers) and globally the sixth leading cause of cancer death in males. This book is a summary of prostate cancer, covering its incidence, epidemiology, and current treatment options. It also serves as an up-to-date review of the status of currently available alternative and complementary medicines for treating prostate cancer, including various plant extracts, herbal formulations, natural products, yoga, acupuncture, Ayurveda, homeopathy, and Siddha medicines used in prostate cancer therapy. |
| brca therapy for prostate cancer: Early Detection of Prostate Cancer, An Issue of Urologic Clinics Stacy Loeb, 2014-05-28 PSA screening remains highly controversial due to several important disadvantages. More PSA is produced with prostatic enlargement and in other benign conditions such as urinary tract infections. False positive tests can then lead to unnecessary diagnostic workup with invasive prostate biopsy. Another major problem with screening programs in general is overdiagnosis of cancers that would not have caused harm during the patient's lifetime. For example, many prostate cancers have a relatively indolent behavior so may not require diagnosis or treatment in a patient with limited life expectancy. All forms of prostate cancer treatment have potential urinary and sexual side effects, so reducing overdiagnosis and overtreatment are critical public health issues. Because screening has many proven benefits but also significant harms, there are widely disparate guidelines on prostate cancer screening from major organizations worldwide. This issue of the Urologic Clinics will provide insights into the many different prostate cancer guidelines and related policy issues. |
| brca therapy for prostate cancer: Prostate Cancer Ravinder Mohan, 2016-09-28 Prostate cancer is diagnosed commonly in the course of general health screening. Very often it is difficult to tell whether the cancer will be aggressive and lethal or will be so slow growing that it will not affect the patient's survival. Treatment can have a major impact on the patient's health-related quality of life. This book presents cutting-edge research in predicting the behavior of localized and metastatic cancer, targeted treatment of cancer that has spread minimally, response to newer methods of treatment, and rehabilitation of patients. |
| brca therapy for prostate cancer: Castration Resistant Prostate Cancer, An Issue of Urologic Clinics Adam S. Kibel, 2012-11-28 Castrate Resistant Prostate Cancer is advanced disease that has stopped responding to hormone therapy. This issue of the Urologic Clinics focuses on the various forms of therapy including immunotherapy, first line chemotherapy, and novel targeted agents. Articles on defining the diseae and palliative care are also included. |
| brca therapy for prostate cancer: DeVita, Hellman, and Rosenberg's Cancer Vincent T. DeVita, Steven A. Rosenberg, Theodore S. Lawrence, 2018-11-16 Publisher's Note: Products purchased from 3rd Party sellers are not guaranteed by the Publisher for quality, authenticity, or access to any online entitlements included with the product. Now updated online for the life of the edition, DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th Edition keeps you up to date in this fast-changing field. Every quarter, your eBook will be updated with late-breaking developments in oncology, including new drugs, clinical trials, and more. |
| brca therapy for prostate cancer: Targeted Therapy in Translational Cancer Research Apostolia-Maria Tsimberidou, Razelle Kurzrock, Kenneth C. Anderson, 2015-10-08 Targeted Therapy in Translational Cancer Research for the Translational Oncology series provides a comprehensive overview of recent developments in our understanding of tumor biology, elucidates the roles of targets and pathways involved in carcinogenesis, and describes current state-of-the-art anticancer therapy, as well as the most promising areas of translational research and targeted therapy. Introduces cutting-edge ‘bench to bedside and back’ breakthroughs which have transformed the diagnosis, prognosis, and treatment of cancer Covers basic principles of targeted therapy, including immunotherapy and the roles of cancer stem cells, the microenvironment, angiogenesis, epigenetics, microRNAs, and functional imaging in precision medicine Summarises major advances in therapeutic management of hematologic malignancies and solid tumors using conventional therapy, targeted therapy, immunotherapy, or novel treatment modalities |
| brca therapy for prostate cancer: Prostate Cancer Jack H. Mydlo, Ciril J. Godec, 2003-07-11 An important translational book bridging the gap between science and clinical medicine, Prostate Cancer reviews the biological processes that can be implicated in the disease, reviews current treatments, highlighting the pitfalls where relevant and examines the scientific developments that might result in novel treatments in the future.Key Features* Provides a translational resource for scientists and clinicians working on prostate cancer* Reviews current surgical interventions and highlights their related pitfalls* Presents the latest laparoscopic techniques with figures and illustrations of step-by-step procedures* Offers insight into the potential for novel approaches to treatment in the future* Includes personal perspectives from patients |
| brca therapy for prostate cancer: Management of Castration Resistant Prostate Cancer Fred Saad, Mario A. Eisenberger, 2014-08-20 This volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in depth review of proven therapeutic options, including bone targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigations are also reviewed. The text provides up to date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence based medicine. As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this challenging malignancy. |
Clinical Guidance for BRCA Gene Testing for Hormone …
hormone-relapsed metastatic prostate cancer (Valsecchi et al., 2023). Individuals with a germline BRCA variant have an increased risk of developing breast, ovarian, prostate and pancreatic …
Frequency of BRCA mutations and co-occurring alterations in …
We examined the presence of somatic BRCA mutations (detected in tumor), in a population of prostate cancer patients. Comparisons between BRCA-mutated and BRCA-wildtype patients …
BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in …
high gLOH scores in 40% and 25% of prostate cancers, respectively; the proportion of the cancer genome under LOH (% gLOH) was slightly higher in prostate tumors with biallelic BRCA1 …
Caring for Patients With Prostate Cancer Who Are BRCA …
BRCA MUTATIONS IN PROSTATE CANCER Estimates of the relative risk of PCa for men with BRCA1 and BRCA2 mutations have varied, but recent data suggest that it is 3.75-fold for …
Guide for BRCA testing in prostate cancer - Lynparza
LYNPARZA is indicated as monotherapy for patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1- and/or BRCA2-mutations (germline and/or somatic) who have …
Therapeutic sensitivity to standard treatments in BRCA …
BACKGROUND: Recent oncology guidelines recommend BRCA1/2 testing for a wide range of prostate cancer (PCa) patients. In addition, PARP inhibitors are available for mutation-positive …
THE ONLY FDA-APPROVED DUAL ACTION TABLET FOR …
with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for …
YOUR SHIELD AGAINST PROGRESSION IN ADVANCED …
*RUBRACA treats metastatic castration-resistant prostate cancer, or mCRPC, which is prostate cancer that has spread to other parts of the body (metastatic) and that no longer responds to …
Policy Statement - Blue Shield of California
Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2) Androgen deprivation therapy (ADT) is usually the initial treatment for patients with advanced prostate cancer. …
Not a real caregiver or patient. Why BRCA matters in
LYNPARZA is a prescription medicine used to treat adults who have prostate cancer with a certain type of abnormal inherited or acquired BRCA gene that has spread to other parts of the …
BRCA Mutations in Prostate Cancer: Assessment, Implications …
we explore the mechanisms of DNA repair, potential for genomic analysis of prostate cancer and therapeutics of PARP inhibitors along with their safety profile. Keywords: prostate cancer; …
Real-world treatment patterns in patients with BRCA 1/2 …
Real-world treatment patterns in patients with BRCA 1/2-positive (BRCA+) meta-static castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy. Mehmet Asim Bilen, Ibrahim …
Patients receiving RUBRACA for mCRPC should also receive a …
BRCA. mutation treated with Rubraca, MDS/AML occurred in 9 out of 129 (7%) patients treated with Rubraca and 4 out of 66 (6%) patients treated with placebo. The duration of therapy with …
BRCA Genes: The Role in Genome Stability, Cancer Stemness …
the role of BRCA mutations in tumor initiation, regulation of cancer stemness, therapy resistance and tumor progression. Key words: BRCA1, BRCA2, genomic instability, cancer stem cells, …
The Relevance of BRCA Genetics to Prostate Cancer …
In this article, we review the role of BRCA genes in the pathogenesis and clinical course of pros-tate cancer. We also discuss the molecular mechanisms of action and the therapeutic …
Impact of germline vs somatic BRCA mutation status on the …
Background: Rucaparib significantly improved radiographic progression-free survival (rPFS) in men with BRCA-mutated chemotherapy-na ̈ıve metastatic castration-resistant prostate cancer …
The cost-effectiveness of germline BRCA testing-guided …
Results: Compared to standard care, BRCA testing-guided olaparib treatment was associated with an incremental cost of AU$7,841 and a gain of 0.06 quality-adjusted life-years (QALYs). …
Rucaparib in Men With Metastatic Castration-Resistant …
Aug 14, 2020 · therapy and taxane chemotherapy have led to improved outcomes for men with metastatic castration-resistant prostate cancer (mCRPC).1-4 However, patients will eventually …
Impact of BRCA status in patients with castrate-resistant …
Background: ARTO (NCT03449719) was a multicenter randomized phase II trial exploring the benefit of concomitant Abiraterone acetate and stereotactic body radiotherapy (SBRT) admin …
Cancer-control outcomes of metastatic castration resistant …
Methods: We relied on the FRAMCAP database and compared progression-free (PFS) and overall survival (OS) rates of mCRPC patients with Breast Cancer related antigen (BRCA) or …
Clinical Guidance for BRCA Gene Testing for Hormone …
hormone-relapsed metastatic prostate cancer (Valsecchi et al., 2023). Individuals with a germline BRCA variant have an increased risk of developing breast, ovarian, prostate and pancreatic cancer.
Frequency of BRCA mutations and co-occurring alterations …
We examined the presence of somatic BRCA mutations (detected in tumor), in a population of prostate cancer patients. Comparisons between BRCA-mutated and BRCA-wildtype patients …
BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in …
high gLOH scores in 40% and 25% of prostate cancers, respectively; the proportion of the cancer genome under LOH (% gLOH) was slightly higher in prostate tumors with biallelic BRCA1 versus …
Caring for Patients With Prostate Cancer Who Are BRCA …
BRCA MUTATIONS IN PROSTATE CANCER Estimates of the relative risk of PCa for men with BRCA1 and BRCA2 mutations have varied, but recent data suggest that it is 3.75-fold for BRCA1 …
Guide for BRCA testing in prostate cancer - Lynparza
LYNPARZA is indicated as monotherapy for patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1- and/or BRCA2-mutations (germline and/or somatic) who have …
Therapeutic sensitivity to standard treatments in BRCA positive …
BACKGROUND: Recent oncology guidelines recommend BRCA1/2 testing for a wide range of prostate cancer (PCa) patients. In addition, PARP inhibitors are available for mutation-positive …
THE ONLY FDA-APPROVED DUAL ACTION TABLET FOR …
with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for …
YOUR SHIELD AGAINST PROGRESSION IN ADVANCED …
*RUBRACA treats metastatic castration-resistant prostate cancer, or mCRPC, which is prostate cancer that has spread to other parts of the body (metastatic) and that no longer responds to …
Policy Statement - Blue Shield of California
Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2) Androgen deprivation therapy (ADT) is usually the initial treatment for patients with advanced prostate cancer. Disease …
Not a real caregiver or patient. Why BRCA matters in
LYNPARZA is a prescription medicine used to treat adults who have prostate cancer with a certain type of abnormal inherited or acquired BRCA gene that has spread to other parts of the body …
BRCA Mutations in Prostate Cancer: Assessment, …
we explore the mechanisms of DNA repair, potential for genomic analysis of prostate cancer and therapeutics of PARP inhibitors along with their safety profile. Keywords: prostate cancer; DNA …
Real-world treatment patterns in patients with BRCA 1/2 …
Real-world treatment patterns in patients with BRCA 1/2-positive (BRCA+) meta-static castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy. Mehmet Asim Bilen, Ibrahim …
Patients receiving RUBRACA for mCRPC should also receive a …
BRCA. mutation treated with Rubraca, MDS/AML occurred in 9 out of 129 (7%) patients treated with Rubraca and 4 out of 66 (6%) patients treated with placebo. The duration of therapy with …
BRCA Genes: The Role in Genome Stability, Cancer Stemness …
the role of BRCA mutations in tumor initiation, regulation of cancer stemness, therapy resistance and tumor progression. Key words: BRCA1, BRCA2, genomic instability, cancer stem cells, cancer …
The Relevance of BRCA Genetics to Prostate Cancer …
In this article, we review the role of BRCA genes in the pathogenesis and clinical course of pros-tate cancer. We also discuss the molecular mechanisms of action and the therapeutic implications of …
Impact of germline vs somatic BRCA mutation status on the …
Background: Rucaparib significantly improved radiographic progression-free survival (rPFS) in men with BRCA-mutated chemotherapy-na ̈ıve metastatic castration-resistant prostate cancer …
The cost-effectiveness of germline BRCA testing-guided …
Results: Compared to standard care, BRCA testing-guided olaparib treatment was associated with an incremental cost of AU$7,841 and a gain of 0.06 quality-adjusted life-years (QALYs). The …
Rucaparib in Men With Metastatic Castration-Resistant …
Aug 14, 2020 · therapy and taxane chemotherapy have led to improved outcomes for men with metastatic castration-resistant prostate cancer (mCRPC).1-4 However, patients will eventually …
Impact of BRCA status in patients with castrate-resistant …
Background: ARTO (NCT03449719) was a multicenter randomized phase II trial exploring the benefit of concomitant Abiraterone acetate and stereotactic body radiotherapy (SBRT) admin …
Cancer-control outcomes of metastatic castration resistant …
Methods: We relied on the FRAMCAP database and compared progression-free (PFS) and overall survival (OS) rates of mCRPC patients with Breast Cancer related antigen (BRCA) or tumor …
